Town & Country Bank & Trust CO dba First Bankers Trust CO Acquires 2,333 Shares of Thermo Fisher Scientific Inc. $TMO

Town & Country Bank & Trust CO dba First Bankers Trust CO lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 91.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,872 shares of the medical research company’s stock after buying an additional 2,333 shares during the period. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Thermo Fisher Scientific were worth $2,363,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of TMO. Brighton Jones LLC lifted its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Consolidated Portfolio Review Corp boosted its position in Thermo Fisher Scientific by 18.4% in the 2nd quarter. Consolidated Portfolio Review Corp now owns 809 shares of the medical research company’s stock valued at $328,000 after buying an additional 126 shares during the last quarter. B.O.S.S. Retirement Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 10.1% in the second quarter. B.O.S.S. Retirement Advisors LLC now owns 590 shares of the medical research company’s stock worth $239,000 after purchasing an additional 54 shares in the last quarter. Finally, Community Financial Services Group LLC grew its holdings in shares of Thermo Fisher Scientific by 6.4% during the second quarter. Community Financial Services Group LLC now owns 743 shares of the medical research company’s stock valued at $301,000 after buying an additional 45 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 2.4%

Shares of TMO opened at $593.16 on Friday. The firm has a market cap of $222.86 billion, a P/E ratio of 34.27, a P/E/G ratio of 3.99 and a beta of 0.91. The stock has a 50 day simple moving average of $594.14 and a two-hundred day simple moving average of $536.01. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping the consensus estimate of $6.44 by $0.13. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were issued a $0.43 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its board has approved a share buyback program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

TMO has been the topic of several research analyst reports. Evercore ISI reaffirmed an “outperform” rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. The Goldman Sachs Group assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price target for the company. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a research note on Sunday, December 7th. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus boosted their price target on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $626.79.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $6.57 vs. consensus ~$6.44 and revenue $12.21B vs. ~$11.95B, showing 7% sales growth and reinforcing demand from pharma and life‑sciences customers. Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management disclosed potential EPS upside from the Clario deal, which could be accretive and support longer‑term earnings growth if integration goes as planned. Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS
• Positive Sentiment: Some analysts remain bullish — William Blair maintained a Buy on TMO, citing resilient organic growth and stabilizing end markets. Thermo Fisher Scientific: Resilient Organic Growth and Stabilizing End-Markets Support Sustained Buy Rating
• Neutral Sentiment: Investor presentation and earnings call provide detail on segment performance, but no near-term catalytic change was signaled beyond the guidance update. Thermo Fisher Scientific Inc. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: FY2026 guidance came in cautious: EPS $24.220–24.800 (vs. consensus ~24.64) and revenue $46.3B–$47.2B (vs. consensus ~46.5B), implying only 4%–6% growth and modest organic demand — investors focused on the conservative tone. Thermo Fisher stock slides on cautious profit guidance
• Negative Sentiment: Management signaled margin pressure and cautious profit expectations for 2026, which pressured the stock despite the Q4 beat. Thermo Fisher slips after issuing 2026 outlook (update)

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the transaction, the executive vice president directly owned 18,731 shares in the company, valued at approximately $11,238,600. The trade was a 36.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michel Lagarde sold 22,046 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the transaction, the chief operating officer owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. This trade represents a 20.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 124,517 shares of company stock valued at $72,363,568. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.